Symptomatic Uses of Caffeine in Patients with Cancer

Jacox A. , Carr D.B. , Payne R. , Berde C.B. , Breitbart W. , Cain J.M. , Chapman C.R. Management of Cancer Pain. Clinical Practice Guidelines No.9. AHCPR Publication No. 94-0592. Rockville, Maryland. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, March 1994.

Kerrihard T. , Breitbart W. , Dent R. , Strout D. Anxiety in patients with cancer and human immunodeficiency virus. Semin Clin Neuropsychiatry 1999; 4: 114–32.

Mercadante S. , Serretta R. , Casuccio A. Effects of caffeine as an adjuvant to morphine in advanced cancer patients: a randomized, double-blind, placebo controlled, crossover study. J Pain Symptom Manage 2001; 21: 369–372.

Rush C.R. , Higgins S.T. , Bickel W.K. , Hughes S.R.J. Acute behavioral effects of lorazepam and caffeine, alone and in combination, in humans. Behav Pharmacol 1994; 5: 245–254.

Manila M.J. , and Nuotto E. Caffeine and theophylline counteract diazepam effects in man. Med Biol 1983; 61: 337–343.

Johnson L.C. , Spinweber C.L. , Gomez S.A. Benzodiazepines and caffeine: effect on daytime sleepiness, performance and mood. Psychopharmacology 1990; 101: 160–167.

Mattila M.J. , Vainio P. , Nurmineri M.L. , Vanakoski J. , Seppala T. Midazolam 12 mg is moderately counteracted by 250 mg of caffeine in man. Int J Clin Pharmacol Ther 2000; 38: 581–587.

Beaver W.T. Caffeine revisited. JAMA 1984; 251: 1732–1733.

Laska E.M. , Sunshine A. , Mueller F. , Elvers W.B. , Siegel C. , Rubin A. Caffeine as an analgesic adjuvant. JAMA 1984; 251: 1711–1718.

Quay MC H.J. , Angell K. , Carroll D. , Moore R.A. , Juniper R.P. Ibuprofen compared with ibuprofen plus caffeine after third molar surgery. Pain 1996; 66: 247–251.

Rubin A. , Winter L. Jr. A double-blind randomized study of an aspirin/caffeine combination versus acetaminophen versus placebo in patients with moderate to severe postpartum pain. J Int Med Res 1984; 12: 338–345.

Schachtel B.P. , Filligim J.M. , Lane A.C. , Thoden W.R. , Baybutt Rl Caffeine as an analgesic adjuvant: A double-blind study comparing aspirin with caffeine to aspirin and placebo in patients with sore throat. Arch Intern Med 1991; 151: 733–737.

Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995; 49: 37–50

Aranda J.V. , and Turmen T. Methylxanthines in apnea of prematurity. Clin Perinatal 1979; 6: 87–108.

Bhatia J. Current options in the management of apnea of prematurity. Clin Pediatr 2000, 39: 327–336.

Migliardi J.R. , Armellino J.J. , Friedman M. , Gillings D.B. , Beaver W.T. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994; 56: 576–586.

Hindmarch I. , Rigney U. , Stanley N. , Quinlan P. , Rycroft J. , Lane J. A naturalistic investigation of the effects of daylong consumption of tea, coffee and water on alertness, sleep onset and sleep quality. Psychopharmacology 2000; 149: 203–216.

Bruera E. , Macmillan K. , MacDonald R.N. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989; 39: 13–16.

Södgren P. , Banning A. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain 1989; 39: 5–11.

Sjögren P. Psychomotor and cognitive functioning in cancer patients. Acta Anesthesiol Scand 1997; 41: 159–161.

Foley K.M. Supportive care and quality of life. In: DeVita V.T. , Hellman S. , Rosenberg S.A. (eds). Cancer: principles and practice of oncology. 5th edition. Philadelphia: Lippincott-Raven Publishers, 1997; p. 2827.

Zacny J.P. A review of the effects of opioids on psychomotor and cognitive functioning in humans. Exp Clin Psychopharmacol 1995; 3: 432–466.

DiGregorio G.J. , Barbieri E.J. , Sterling G.H. , Camp J.F. , Prout M.F. Stimulants and antidepressants. In: DiGregorio G.J. , Barbieri E.J. , Sterling G.H. , Camp J.F. , Prout M.F. (eds). Handbook of Pain Management. 3rd edition. West Chester, Pennsylvania: Medical Surveillance, Inc., 1991; p. 71, p. 148.

Watling C.J. , Payne R. Management strategies for pain in the cancer patient. In: Ashburn M.A. , Rice L.J. (eds). The Management of Pain. New York: Churchill Livingstone, Inc., 1998; p. 482.

Portenoy R.K. Adjuvant analgesics in pain management. In: Doyle D. , Hanks G.W.C. , MacDonald N. (eds). Oxford Textbook of Palliative Medicine. 2nd edition. New York: Oxford Medical Publications, 1998; p. 379, p. 760.

Witt S.D. Patients with Acquired Immune Deficiency Syndrome. In: Ferrell B.R. , Coyle N. (eds). Textbook of Palliative Nursing. New York: Oxford University Press, 2001; p. 491.

Debas H.T. , Cohen M.M. , Holubinsky I.B. , Harrison R.C. Caffeine-stimulated acid and pepsin secretion: dose response studies. Scand J Gastroenterol 1971; 6: 453–457.

Cohen S. , Booth G.H. Gastric acid secretion and lower-esophageal-sphincter pressure in response to coffee and caffeine. N Engl J Med 1975; 298: 897–899.

Abo M. , Kono T. , Chen J.D.Z. Effects of caffeine on gastrointestinal myoelectric activity and colonic spike activity in dogs. Scand J Gastroenter 2000; 35: 368–374.

Fredholm B.B. Gastrointestinal and metabolic effects of methylxanthines. Prog Clin Biol Res 1984; 158: 331–354.

Kentrup H. , Baisch H.J. , Kusenbach G. , Heimann G. , Skopnik H. Effect of cisapride on acid gastro-esophageal reflux during treatment with caffeine. Biol Neonate 2000; 77: 92–95.

Homsi J. , Walsh D. , Nelson K.A. Psychostimulants in supportive care. Support Care Cancer 2000; 8: 385–397.

U.S. Department of Health and Human Services, Food and Drug Administration. Code of Federal Regulations. Title 21, volume 5 (21CFR340). Revised April 1, 2002. Rockville, Maryland: U.S. Food and Drug Administration, 2002; pp. 238–239.